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Abstract Recombinant factor XIII-A2 (rFXIII-A2) was developed for prophylaxis and treatment of bleeds
in patients with congenital FXIII A-subunit deﬁciency. mentor™2 (NCT00978380), a multi-
national, open-label, single-arm, multiple-dosing extension to the pivotal mentor™1 trial,
assessed long-term safety and efﬁcacy of rFXIII-A2 prophylaxis in eligible patients (patients
with severe [<0.05 IU/mL] congenital FXIII subunit A deﬁciency) aged 6 years. Patients
received35 IU/kg rFXIII-A2 (exactdosing)every28  2days for52weeks.Primaryendpoint
was safety (adverse events including immunogenicity); secondary endpoints were rate of
bleeds requiring FXIII treatment, haemostatic response after one 35 IU/kg rFXIII-A2 dose for
breakthrough bleeds and withdrawals due to lack of rFXIII-A2 efﬁcacy. Steady-state
pharmacokinetic variables were also summarized. Elective surgery was permitted during
the treatment period. Sixty patients were exposed to rFXIII-A2; their median age was
26.0 years (range: 7.0–77.0). rFXIII-A2 was well tolerated without any safety concerns. No
non-neutralizing or neutralizing antibodies (inhibitors) against FXIII were detected. Mean
annualized bleeding rate (ABR) was 0.043/patient-year. Mean spontaneous ABR was
0.011/patient-year. No patients withdrew due to lack of efﬁcacy. Geometric mean FXIII
trough level was 0.17 IU/mL. Geometric terminal half-life was 13.7 days. rFXIII-A2 prophylaxis
provided sufﬁcient haemostatic coverage for 12 minor surgeries without the need for
additional FXIII therapy; eight procedures were performed within 7 days of the patient’s last
scheduled rFXIII-A2 dose, and four were performed 10 to 21 days after the last dose.
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Introduction
Factor XIII (FXIII) is the terminal enzyme in the blood
coagulation cascade and essential for cross-linking ﬁbrin
molecules to form an effective and stable blood clot. In
plasma, FXIII circulates as an inactive heterotetramer com-
posed of two catalytic FXIII A-subunits and two carrier FXIII
B-subunits (FXIII-A2B2).1,2 A deﬁciency or dysfunction of
either the A or B subunit can result in FXIII deﬁciency.
Congenital FXIII deﬁciency is a rare and serious autosomal
recessive coagulation disorder with a high risk of life-threa-
tening bleeding complications.3 The prevalence of congenital
FXIII deﬁciency is estimated to be approximately 1 in 1 to 2
million people worldwide.4,5 Its incidence is much higher in
certain parts of the world where consanguinity is common;
this is particularly the case in Iran, which has the highest
reported rate of FXIII deﬁciency.6 Patients with congenital
FXIII deﬁciency experience major spontaneous bleeding
episodes (e.g. intracranial, intramuscular and gastrointest-
inal tract bleeds) more frequently than patients with most
other rare bleeding disorders4 and are at a high risk of
intraoperative and delayed postoperative bleeds.3,7,8
The most common form of congenital FXIII deﬁciency is A-
subunit deﬁciency, which ismore severe and accounts for 95%
of all severe deﬁciency, while B-subunit deﬁciency is very
rare.9 Patients with congenital FXIII deﬁciency require FXIII
replacement to treat bleeds and, even more importantly, to
prevent them (prophylaxis). The long half-life of FXIII, com-
bined with the high risk of life-threatening bleeds associated
with FXIII deﬁciency, makes prophylaxis an attractive and
efﬁcacious treatment option. Thus, prophylaxis is strongly
recommended for all patients with severe FXIII deﬁciency.
Until recently, only plasma-derived sources of FXIII have
been available (fresh frozen plasma [FFP], cryoprecipitate
and plasma-derived FXIII [pdFXIII] concentrate). Such pro-
ducts carry a risk of pathogen transmission10 and do not
contain very concentrated forms of FXIII, such that large
volumes need to be administered; pdFXIII concentrate con-
tains approximately 62.5 U of FXIII/mL.
Recombinant FXIII (rFXIII-A2, Novo Thirteen®; Tretten®,
Novo Nordisk, Bagsværd, Denmark) is the only rFXIII product
available; it contains a 13-fold higher concentration of FXIII
(833 IU/mL) comparedwith pdFXIII.11 rFXIII contains only the
FXIII-A2 subunit, offering a treatment option to prevent bleeds
in patients with the much more common and more severe
form of congenital FXIII deﬁciency—subunit-A deﬁciency.12,13
rFXIII-A2 is a highlypuriﬁedproductmanufactured in Sacchar-
omyces cerevisiae; no human or other mammalian blood or
tissue products are used during its manufacture;14,15 thus,
FXIII-A2 does not carry a risk of contaminationwith infectious
agents, including viruses or prions.16
The efﬁcacyand safety of rFXIII-A2 inpatientswith this rare
bleeding disorder have been demonstrated in a large-scale
clinical trial programme (mentor™). In the pivotal mentor™1
trial with patients aged 6 years, prophylaxis with 35 IU/kg
rFXIII-A2 dosed every 4 weeks provided a good safety proﬁle
and resulted inavery lowmeanannualizedbleeding rate (ABR)
of only 0.138 bleeds/patient-year.17 Similarly, the paediatric
mentor™5 showedexcellent efﬁcacyand safetyof prophylaxis
with 35 IU/kg rFXIII-A2 dosed every 4 weeks in patients aged
<6 years.18 Previous reports have shown similar pharmaco-
kinetics (PK) in young children to that of older children and
adults.19,20 In the mentor™ programme to date, no patients
treated with rFXIII-A2 have developed FXIII-neutralizing anti-
bodies (i.e., FXIII inhibitors).21
The mentor™2 extension trial is the largest clinical trial
performed to date in patients with congenital FXIII deﬁ-
ciency. Here, we report the long-term safety and efﬁcacy
results for rFXIII-A2 replacement therapy dosed every
4 weeks for bleed prevention and for treatment of break-
through bleeds in children, adolescents and adults with
congenital FXIII A-subunit deﬁciency. As mentor™2 per-
mitted elective surgeries, we also report data on minor
surgical procedures conducted in patients receiving rFXIII-
A2 prophylaxis during the trial.
Methods
As the mentor™2 trial is an extension of the pivotal
mentor™1 trial, the methods have been reported pre-
viously,17,22 but will be brieﬂy described here.
Trial Conduct
Prior to the start of the trial, written informed consent was
obtained from each patient. In addition, the protocol, consent
form and patient information sheet were reviewed and
approved according to local regulations by appropriate health
authorities and independent ethics committees/institutional
review boards. The trial was conducted in accordance
with the U.S. Food and Drug Administration Code of Federal
Regulations,23 the International Conference onHarmonisation
Good Clinical Practice Guidelines,24 applicable regulatory
requirements and the Declaration of Helsinki.25
Patients
Eligible patients were aged 6 years, weighed 20 kg and
had a diagnosis of congenital FXIII A-subunit deﬁciency (FXIII
A subunit level of <0.05 IU/mL with genetic conﬁrmation
demonstrating homozygosity or compound heterozygosity
for FXIII A-subunit deﬁciency mutation[s]). Key exclusion
criteria were any known congenital or acquired coagulation
disorder, other than congenital FXIII deﬁciency; a known
history of thromboembolic events; known inhibitors to FXIII;
and any medical, social or psychosocial factors expected to
impact compliance or safety.
Trial Design
Thementor™2trial (►Fig. 1)wasamulticentre,multinational,
open-label, single-arm, multiple-dosing, non-randomized
safety extension to the pivotal mentor™1 trial.17 Important
protocol amendments to mentor™2 included the addition of
newpatientswhodidnotenrol frommentor™1and theoption
to treat breakthrough bleeds with rFXIII-A2 (introduced in
2012). Inclusion of re-enrolled patients was also allowed. The
per-protocol prophylaxis dose of rFXIII-A2was 35 IU/kg (exact
dosing given;achieving this requiredwastageofproductwhen
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calculated amountwas less than full vial of 2,500U/vial), given
intravenously every 28  2 days for a minimum of 52 weeks.
Patients who experienced breakthrough bleeds and required
additional FXIII treatmentwere tobe treatedaccording to local
standardpractice,with theoption for treatmentwith rFXIII-A2
(a single 35 IU/kg dose was to be used, if possible).
Elective surgery was permitted during the treatment
period. For any surgical procedure, if investigators judged
that additional FXIII substitution was required, then pdFXIII
was to be administered according to local practice. After any
administration of pdFXIII to cover surgery, patients would
continue with the original rFXIII-A2 replacement schedule
(i.e., dosing every 4 weeks), with the next dose administered
28  2 days after the last scheduled dose.
Objectives and Endpoints
The primary objective was to assess the long-term safety
(including any antibody development against rFXIII-A2—if
any) of replacement therapy every 4 weeks with rFXIII-A2
when used for the prevention of bleeding episodes and for the
treatment of breakthrough bleeds in patients with congenital
FXIIIA-subunitdeﬁciency. Importantendpoints comprised the
assessment of all adverse events (AEs; both serious and non-
serious, including any AEs of special interest, such as antibody
development against rFXIII-A2, medication errors or throm-
boembolic events). Additional secondary safety endpoints
comprised any abnormalities in laboratory variables, vital
signs and body measurements. Other secondary objectives
were to evaluate the efﬁcacy and summarize the steady-state
PK proﬁle of replacement therapy every 4 weeks with rFXIII-
A2. Laboratory sampling and medical assessments were per-
formed every 12 weeks throughout the treatment period.
Efﬁcacyassessments, performed by the patient or caregiver
in consultationwith the investigator, were based on a 4-point
scale (“Excellent”, “Good/Effective”, “Moderate/Partly Effec-
tive” and “Poor”). Haemostatic outcome was only collected
for bleeding episodes treated with rFXIII-A2. The number of
patients withdrawn due to lack of treatment efﬁcacy was also
recorded.
The Berichrom® FXIII chromogenic activity assay (Siemens
Healthcare, Erlangen, Germany) was used to measure FXIII
activity.17,22 A subgroup of patients participated in steady-
state PK assessments inwhichblood sampleswere collected at
pre-dose, 1 and 2 hours and at 3, 7, 14, 21 and 28 days post-
dose. Only patients who had already received a minimum of
10 doses of rFXIII-A2 participated in the PK assessment. PK
methods are explained in more detail in Kerlin et al.22
For patients undergoing elective surgery, the following
assessments were made during the perioperative period:
type and severity (major/minor) of surgery, timing of the
surgery in relation to the last rFXIII-A2 dose, haemoglobin
levels pre- and post-surgery, dose regimen of pdFXIII, addi-
tional haemostatic drugs used, the amount of blood and blood
products transfused and AEs. Minor surgery was deﬁned as
any invasive operative procedure in which only skin, mucous
membranes or superﬁcial connective tissuewasmanipulated.
All AEs, concomitant medication and bleeds were monitored
up to 4 weeks after the date of surgery.
Antibody Assays
An anti-rFXIII antibody enzyme-linked immunosorbent
assay (ELISA) and an in vitro neutralizing antibody assay
were used for immune response screening, conﬁrmation and
antibody characterization.17
Statistical Analysis
The sample size for this study was estimated to cover the
patients migrating from mentor™1 and augmented by 10 to
20 additional patients who had not originally participated in
mentor™1.
Sixty unique patients enrolled into mentor™2. All patients
were included in the full analysis set and all safety endpoints
were summarized using descriptive statistics. As in men-
tor™1,17 ABR was based on the number of bleeding episodes
requiring FXIII treatment and was evaluated by a Poisson
regression model with baseline age as a covariate and total
observation time as an offset. The number of bleeds requiring
treatment with a FXIII-containing product, haemostatic
response to FXIII-A2 treatment and number of patients with-
drawn due to lack of treatment efﬁcacy were tabulated. PK
variableswere calculated based on non-compartmentalmeth-
odswithout prior baseline adjustments, as described by Kerlin
et al.22
Results
Patients
Sixty patients (16 children aged 7 to<18 years and 44 adults
aged 18–77 years) from 34 centres in 12 countries (Austria,
Canada, Finland, France, Germany, Israel, Italy, Japan, Spain,
Fig. 1 Patient disposition. ID, identiﬁcation; N, number of patients;
PK, pharmacokinetics. Note: A total of 60 patients were enrolled and
exposed in the trial, but three were later withdrawn and subsequently
re-enrolled with new patient identiﬁcations, giving rise to a total of
N ¼ 63 patient identiﬁcations. aFrom the mentor™1 trial, there were
34 patients enrolled into mentor™2.
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Switzerland, UK and United States) were enrolled and
exposed to rFXIII-A2 between 21 September 2009 and 20
October 2015. Thirty-four patients were enrolled from the
mentor™1 trial and an additional 26 newly enrolled patients
were included (►Fig. 1). The median age of patients at
enrolment was 26.0 years (range: 7.0–77.0 years;
►Table 1); 16 (26.7%) patients were younger than 18 years.
Themajority of patients weremale (n ¼ 38; 63.3%) andmost
were Caucasians (n ¼ 34; 56.7%).
Eighteenpatients (30.0%)withdrew from the trial (►Fig. 1).
Three withdrew because they became pregnant and ﬁve
because they failed to comply with the trial treatment
or protocol; thus, these eight patients met the protocol-
mandated withdrawal criteria. Two patients were withdrawn
due to non-compliance as they were out of the country for
7weeks. An additional eight patientswithdrew due to “other”
reasons: patient/family withdrew consent without specifying
a reason (n ¼ 5); patient elected to stop study treatment and
receive commercially available rFXIII-A2 (n ¼ 1); patient
undertook a yearlong trip, so could not remain in the study
(n ¼ 1); and patient wished to be treated with commercially
available pdFXIII (n ¼ 1). Of the 18 patients who withdrew,
three later re-enrolled onto the mentor™2 trial and were
given new patient IDs (reasons for initial withdrawal of these
patients were patient wishes, pregnancy and compliance
issues).
Safety
Patients were exposed to a total of 2,410 rFXIII-A2 doses,
corresponding to 186.5 patient-years of cumulative exposure
(an average of 3.1 [range: 0.15–5.37] years per patient).
rFXIII-A2 prophylaxis once every 4 weeks was well tolerated.
There were 920 treatment-emergent AEs reported in 56
(93.3%) patients (►Table 2); headache and nasopharyngitis
were the most common AEs. The vast majority of AEs (904/
920; 98.3%) were mild or moderate in severity, while 16/920
(1.7%) were severe. Of the 920 AEs, 19 (occurring in 12
patients) were considered serious, based on seriousness
criteria. All 19 serious AEs (SAE) were evaluated as unlikely
to be related to rFXIII-A2 treatment (►Table 3); all of these
patients with SAEs continued FXIII-A2 treatment at the same
dose. Seven AEs in six patients were evaluated as being
possibly/probably related to rFXIII-A2 (►Table 3); however,
all six patients recovered. There were 12 AEs of special
interest in eight patients, 10 of which were small deviations
from the correct dose, ranging from 28.2 to 37.6 IU/kg
(►Table 3). One event of overdose (2.3 times the planned
dose) was evaluated by the investigator as mild and did not
have any clinical consequences. All AEs of special interest
were considered mild and the patients recovered. None of
these medication errors were judged to have had an impact
on the results of the trial.
No anti-rFXIII antibodies (neutralizing or non-neutralizing)
were detected in the mentor™2 trial. There were no thrombo-
embolic events, fatal AEs or AEs leading to withdrawal
(►Table 2) andnoanaphylacticor allergic reactions to rFXIII-A2.
Efﬁcacy
No patients were withdrawn due to lack of rFXIII-A2 efﬁcacy.
During the trial, the rate of FXIII treatment requiring
bleeds was low: eight bleeds in seven patients. Six bleeds
were trauma induced and twowere spontaneous (►Table 4).
The spontaneous bleedswere epistaxis (picked nose) in an 8-
year-old patient, and a muscular bleed (after considerable
physical work) in a 25-year-old patient. There was one
intracranial bleeding episode that was the result of a head
injury in a severe car accident, occurring 4 days after the
patient’s last prophylactic dose of rFXIII-A2. The intracranial
bleedwas considered unrelated to rFXIII-A2 treatment by the
Table 1 Baseline characteristics
Total
Patients (N)a 60
Age, median (range), y 26.0 (7.0–77.0)
Adults (18 y of age); adolescents/
children (6 to <18 y of age)
44:16
Sex (female:male) 22:38
Weight, mean (SD), kg 67.7 (19.9)
Body mass index, mean (SD), kg/m2 24.3 (5.3)
Race, N (%)
Caucasian 34 (56.7)
Asian 9 (15.0)
Black or African American 6 (10.0)
American Indian or Alaskan Native 1 (1.7)
Other 6 (10.0)
Unknown 4 (6.7)
Abbreviations: N, number of patients; SD, standard deviation.
aIncludes three patients who withdrew from the trial and were subse-
quently re-enrolled with new patient IDs.
Table 2 Summary of adverse events (AEs)
Summary Number of patientsa/
events
All AEs 56 (93.3%); 920
AEs by severity
Severe 12 (20%); 16
Moderate 26 (43.3%); 119
Mild 54 (90%); 785
AEs by relationship to rFXIII-A2 treatment
Probably or possibly related 6 (10%); 7
Unlikely related 56 (93.3%); 890
Missing 6 (10%); 23
AEs leading to withdrawal 0
Abbreviations: rFXIII-A2, recombinant factor XIII-A2; %, percentage of
patients with AEs.
Note: Non-serious AEs that were symptoms of other AEs were not
included.
aWhen summarizing AEs, the three re-enrolled patients were assigned
their initial patient IDs to avoid double counting.
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investigator. No internal organ bleeds or severe gastrointest-
inal bleeds occurred. The majority of patients (four of seven)
who had a FXIII treatment requiring bleed were younger
than 18 years (►Table 5). Three bleeds occurred within the
ﬁrst 14 days post-rFXIII-A2 infusion when FXIII levels were
predicted to be greater than 0.3 IU/mL in most patients,22
while ﬁve occurred between days 17 and 24 post-rFXIII-A2
infusion. As such, the mean ABR for patients on study
(treated with 35 IU/kg rFXIII-A2 every 4 weeks) was 0.043
(0.032 and 0.011 for traumatic and spontaneous bleeds/
patient-year, respectively; ►Table 4). This mean ABR
implies only one bleed per 23 patient-years, while the
mean spontaneous bleed ABR of 0.011 bleeds/patient-year
implies one spontaneous bleed per 91 patient-years.
Table 3 Details of serious adverse events (SAEs), possible/probable treatment-related adverse events (AEs) and medical events of
special interest
Type of AE N Description Days since last dose
SAE
Falls or accidents 10 • Five SAE related to motor vehicle accidents in two patients
(female, aged 23; male, aged 29)
• 12 (female, aged 23)
and 4 (male, aged 29)
• Two SAE due to fall/chest injury in one patient
(female, aged 48)
• 7 and 23, respectively
• Two SAE related to a head injury in one patient
(female, aged 8a)
• 8 and 25, respectively
• One SAE related to a laceration to the head in one patient
(male, aged 12)
• 24
Left inguinal hernia 1 Hernia surgical repair under rFXIII-A2 prophylaxis
(male, aged 50)
• 33
Sigmoid diverticulitis 1 Female, aged 57 • 24
Worsening of bilateral
chronic otitis media
1 Male, aged 55 • 11
Ectopic pregnancy 1 Led to termination of pregnancy at gestation week 7 (female,
aged 25)
• 28
Cerebral ischaemia 1 Secondary to accidental, work-related carbon monoxide poi-
soning (male, aged 60; history of diabetes mellitus)
• 8
Headache 1 Admitted to hospital due to headaches (female, aged 8a) • 25
Suicide attempt 1 Overdose with aspirin and ibuprofen (female, aged 14) • 20
Atrial septal defect and
persistent ductal arteriosus
2 277 days (8 months) after a woman (aged 24) withdrew from
trial due to pregnancy her newborn was born with defects
• 277
Possible/probable rFXIII-A2 treatment-related AE
Incorrect dose 1 Accidentally dosed 3.0 mL instead of 3.2 mL (male, aged 15) • 28
Overdose 1 Approximately 2.3 times overdose (80.03 IU/kg instead of 35
IU/kg), no adverse clinical effect (male, aged 8b)
• 29
Limb injury 1 Bleeding under toenail due to trauma (male, aged 22) • 28
Arthralgia 1 Left knee pain (male, aged 8b) • 22
Leukopenia 1 Asymptomatic leukopenia (female, aged 15) • 28
Alanine aminotransferase
increased
1 Two of 42 tests with elevated values of 52 and 61 U/L (male,
aged 26; reference range 6–43 U/L)
• 28
Blood alkaline phosphatase
increased
1 Male, aged 63, with chronic hepatitis and a liver cyst (elevated
values between 126–154 U/L; reference range 35–125 U/L)
• 28
AEs of special interest
Incorrect dose 10 Small deviations from the correct dose (seven patients) –
Overdose 1 Approximately 2.3 times overdose (80 IU/kg instead of 35 IU/
kg), no adverse clinical effect (male, aged 8b)
• 29
Product preparation error 1 Reconstitution with saline (not sterile water; female, aged 14) • 32
Abbreviations: N, number of AEs; rFXIII-A2, recombinant factor XIII-A2.
aTwo different AEs in the same patient.
bThere were two different AEs in this patient (“arthralgia” and “overdose”); the AE “overdose” was considered a possible/probable rFXIII-
A2treatment-related AE and also an AE of special interest. Patient age refers to age at baseline of the mentor™2 trial.
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One traumatic bleedwas successfully treatedwith rFXIII-A2:
the patient suffered a trauma-induced muscular bleed 24 days
after the last rFXIII-A2 dose (►Table 5) and a single rFXIII-A2
dose of 35 IU/kg was administered. The haemostatic response
was rated as excellent. No additional FXIII-containing products
were necessary to treat the bleed.
Pharmacokinetic Analysis
Steady-state PK data with rFXIII-A2 have been previously
reported.22 In the current mentor™2 trial, evaluation of all
available pre-dose samples from all 60 patients revealed a
geometric mean FXIII trough level of 0.17 IU/mL (coefﬁcient
of variation: 0.37). In addition, the geometric mean terminal
half-life of rFXIII-A2 was 13.6 (range: 10.1–24.6) days, in line
with previously reported PK results for rFXIII-A2.22 FXIII
trough levels below 0.10 IU/mL were detected sporadically
throughout the trial: among a total of 2,245 trough level
measurements, only 65 (2.9%) were less than 0.10 IU/mL.
In all patients, individual mean FXIII trough levels were
greater than 0.10 IU/mL.
Surgery
Twelve minor surgical procedures were performed in nine
patients: post-traumatic surgical repair in one patient, and
11 other minor (mostly dental) procedures in eight patients
(►Table 6). Median (range) patient age at the time of surgery
was 31 (19–59) years. Eight of the 12 procedures were
performed within 7 days of the patient’s last scheduled
rFXIII-A2 dose, and four were performed 10 to 21 days after
the last dose. No additional substitution with pdFXIII or
rFXIII-A2 was given for any procedure. Concomitant anti-
ﬁbrinolytics were used in four procedures (tooth extractions
[n ¼ 3] and colonoscopy [n ¼ 1]). In three patients, haemo-
globin levels were available before (9.9, 11.8 and 15.8 g/dL,
respectively) and immediately after surgery (10.3, 11.6 and
16.5 g/dL, respectively), demonstrating that haemoglobin
did not decline in association with surgery. The longest
period between a rFXIII-A2 dose and minor surgery was
3 weeks; based on PK modelling, it was estimated that the
patient would have had a FXIII activity level of 0.19 IU/mL
(►Table 6). There were no reports of unexpected blood loss,
requirements for transfusion with blood or blood products
and no surgical complications related to FXIII deﬁciency or
treatment for any of these 12 procedures.
Discussion
This paper presents the long-term safety and efﬁcacy results
from the mentor™2 extension trial—the largest dataset of
any clinical trial in FXIII deﬁciency involving 186.5 patient-
years’ worth of data. This is also the ﬁrst report on minor
surgical procedures conducted in patients receiving rFXIII-A2
prophylaxis.
Table 4 Bleeding episodes requiring treatment with FXIII
Total
Number of patients 60
Number of patients with
bleeds
7
All bleeds
Number of bleeds 8
Mean ABRa 0.043
Spontaneous bleeds
Number of bleeds 2
Mean ABRa 0.011
Traumatic bleeds
Number of bleeds 6
Mean ABRa 0.032
Abbreviations: ABR, annualized bleeding rate; FXIII, factor XIII.
aCalculated as the number of bleeds divided by the total patient-years
(Poisson estimate).
Table 5 Details of bleeding episodes requiring treatment with FXIII, arranged in ascending age of patients at time of bleed
Agea Gender Bleed type Days since
last dose
Description Treatment
8b Female Traumatic 7 Bruising on arm/soft tissue pdFXIII
8b Female Spontaneous 19 Spontaneous epistaxis (possibly after picking her nose) pdFXIII
10 Male Traumatic 17 Injury (bruises) to left knee while playing soccer pdFXIII
12 Male Traumatic 24 Forehead laceration due to fall on a staircase pdFXIII
16 Male Traumatic 24 Haematoma and swelling of right forearm after a fall rFXIII-A2
23 Female Traumatic 12 Bruises to hip, lumbar spine, sternum and head after
motor vehicle accident
pdFXIII
25 Male Spontaneous 20 Muscular bleed in left shoulder after “massive
physical work”
pdFXIII
29 Male Traumatic 4 Subarachnoid subdural and extradural haemorrhage
after motor vehicle accident
Cryoprecipitate
Abbreviations: FXIII, factor XIII; pdFXIII, plasma-derived FXIII.
aAge at baseline of the mentor™2 trial.
bThe same patient.
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Safety
Inhibitor (neutralizing antibody) development is the most
serious threat associated with the treatment of FXIII deﬁ-
ciency. This has been reported in several patients treated
with pdFXIII-containing products.26 In the current men-
tor™2 trial aswell as in the entirementor™ trial programme,
no patients have developed inhibitors and in the entire
mentor™ trial programme only ﬁve individuals, all younger
than 18 years, have developed transient, non-neutralizing
antibodies to rFXIII-A2 [reviewed in Carcao et al21]. These
antibodies have been shown to have no inhibitory activity
and the individuals did not experience any AEs or bleeding as
a result of or in associationwith these antibodies.11 It should
be noted that no additional patients developed non-neutra-
lizing antibodies in this current mentor™2 trial.
Efﬁcacy
In the mentor™2 trial, rFXIII-A2 prophylaxis (35 IU/kg every
28  2 days) resulted in high FXIII trough levels in all
patients and consequently excellent haemostatic coverage.
This was evident in the absence of spontaneous intracranial,
internal organ or severe gastrointestinal bleeds during the
mentor™2 trial encompassing 186.5 patient-years. Further-
more, there were only two spontaneous bleeds over the
6-year trial duration. It should be noted that on this prophy-
lactic regimen (35 IU/mL every 28  2 days), patients would
be expected to have FXIII levels in the range of normal
(>0.5 IU/mL) for 1 week following an infusion; after this,
their FXIII levels would be expected to be in the mild
deﬁciency range (>0.3–0.5 IU/mL) for another week before
falling into the moderate deﬁciency range (0.05–0.3 IU/mL).
At no time would any patient experience a FXIII level in the
severe (<0.05 IU/mL) deﬁciency range.
No patients withdrew due to lack of efﬁcacy of rFXIII-A2
treatment. The spontaneousABR reported inmentor™2 is com-
parable to that reported for the marketed pdFXIII product.27,28
The treatment of breakthrough bleeds with rFXIII-A2 was
ﬁrst introduced in 2012 as a protocol amendment during the
mentor™2 trial. Given the rarity of bleeds in the mentor™2
trial, only one bleed was treated with rFXIII-A2; the haemo-
static outcome was excellent. Similarly, a recent case study
also reported the rapid and successful treatment of a bleed
(major intramuscular bleed) with 35 IU/kg rFXIII-A2 in a
patient who was not on the mentor™2 trial.29 Further case
reports would provide valuable information on the effective-
ness of rFXIII-A2 for the treatment of breakthrough bleeds.
Surgery
To date, the only published data on surgery in FXIII deﬁciency
derive from a report of six patients receiving pdFXIII to cover
major orminor procedures.7As elective surgerywaspermitted
during mentor™2, this trial provided the ﬁrst data on minor
surgical procedures performed in patients receiving rFXIII-A2
prophylaxis. All 12 minor procedures (1 post-traumatic surgi-
cal repair and11otherprocedures)wereperformedwithin1 to
21days of the last scheduled rFXIII-A2doseandadditional FXIII
substitutionwas not administered for any of these procedures.
Ina fewof these, anti-ﬁbrinolytic therapywasalsogiven. These
ﬁndings suggest that prophylaxiswith35 IU/kg rFXIII-A2 every
4 weeks provides sufﬁcient haemostatic coverage for the
perioperative management of minor surgical procedures in
patients with congenital FXIII deﬁciency, without the need for
Table 6 Minor surgical procedures undertaken during mentor™2
Agea Gender Surgical procedure Days since last
rFXIII-A2 dose
Geometric mean
FXIII activity level
(IU/mL)
44 Female Extraction of tooth 18 and tooth root 17 0 0.83
59 Female Extraction of two teeth 0 0.83
57c Male Ulnar nerve carpal tunnel syndrome repair 1 0.65b
29 Female Colonoscopy 1 0.65b
25 Male Circumcision revision 1 0.65b
33d Female Tooth extraction 2 0.62b
31 Male Upper left molar extraction 4 0.54b
24e Female Extraction of right upper wisdom tooth 7 0.43
19 Male Suture of traumatic cut to left forearm 10 0.34b
31d Female Wisdom tooth extraction 11 0.32b
25e Female Extraction of left upper wisdom tooth 17 0.23b
58c Male Removal of polyp from right internal ear
and partial removal of polyp from left
internal ear
21 0.19
Abbreviations: FXIII, factor XIII; rFXIII-A2, recombinant factor XIII-A2.
aAge at the time of surgery.
bLog-linear interpolated values based on the geometricmean FXIII activity published previously,22 which assumes an exponential decay between two
measurements.
c,d,eThe same patients.
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additional FXIII treatment. While additional FXIII treatment
was not deemed necessary by the investigators for surgeries in
this study, all FXIII treatmentoptions should still be considered
on an individual patient basis.
Of the worldwide number of known patients diagnosed
with congenital FXIII deﬁciency, 4.5% participated in the
mentor™2 trial.30 Despite that, a potential limitation was
the lownumber ofchildren/adolescents (n ¼ 16)participating
in thementor™2 trial; however, the currentmentor™2 results
support thosefromthementor™5 trial,which showedefﬁcacy
and safety in six paediatric patients aged 1 to 4 years, inwhich
rFXIII-A2 prophylaxis was well tolerated and provided appro-
priate haemostatic coverage; the ABR was 0.18
In conclusion, results from the multicentre, multinational
mentor™2 extension trial showed that rFXIII-A2 prophylaxis
every 4weeks iswell toleratedwithout identiﬁed safety issues;
bleeding rates are very low during prophylaxis among patients
of all ages with congenital FXIII A-subunit deﬁciency. None of
the patients receiving rFXIII-A2 as part of the mentor™2 study
developed either non-neutralizing or neutralizing antibodies,
or experienced spontaneous intracranial haemorrhages, severe
bleeds, thromboembolic events, anaphylactic or allergic reac-
tions, exposure to pathogen transmission or any signiﬁcant
changes inhaematologyorclinical chemistry. Inaddition,while
limited to 12 procedures in nine patients, initial data from
mentor™2 forminor surgeries performed in patients receiving
rFXIII-A2prophylaxisarefavourable, andaddto thevery limited
body of evidence currently available on surgery in FXIII-deﬁ-
cient patients.21
What is known about this topic?
• Congenital FXIII A-subunit deﬁciency is a rare, auto-
somal recessive coagulation disorder with a high riskof
life-threatening bleeding.
• Prophylaxis is the preferred treatment option for
patients with FXIII A-subunit deﬁciency.
• rFXIII-A2 is the only recombinant FXIII A2-subunit
product available to prevent bleeds in patients with
congenital FXIII A-subunit deﬁciency.
What does this paper add?
• The mentor™2 trial represents the largest clinical trial
dataset in congenital FXIII A-subunit deﬁciency, invol-
ving 60 unique patients with the disorder.
• rFXIII-A2 35 IU/kg was given once every 4 weeks (for a
total of 186.5 cumulative patient-years) and was well
tolerated without hypersensitivity reactions, throm-
boembolic events or anti-FXIII antibody development.
• rFXIII-A2 provided excellent long-term haemostatic efﬁ-
cacy with a geometric mean FXIII trough of 0.17 IU/mL,
with patients demonstrating a spontaneous ABR that
corresponded toonebleedper91patient-years. rFXIII-A2
prophylaxis allowed for effective haemostasis in 12
minor surgical procedures in nine patients without the
need foradditional FXIII treatment. This is theﬁrst report
on the effectiveness of rFXIII-A2 in the surgical setting.
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